Anti-Mouse CD279 (PD-1) (Clone RMP1-14) - Purified In vivo GOLD Functional Grade Trial Size

Antibody Details

Product Details

Reactivity Species

Mouse

Host Species

Rat

Immunogen

Mouse PD-1 transfected BHK cells

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

Next Day 2-8°C

RRID

AB_2737557

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone RMP1-14 recognizes an epitope on mouse PD-1.

Antigen Distribution

PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.

Background

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

Antigen Details

Protein

PD-1

Ligand/Receptor

PD-L1 (B7-H1), PD-L2

Function

Lymphocyte clonal selection, peripheral tolerance

PubMed

PD-1

NCBI Gene Bank ID

18566

UniProt.org

Information on Uniprot.org

Research Area

Apoptosis

.

Cancer

.

Cell Biology

.

Cell Death

.

Immunology

.

Inhibitory Molecules

.

Tumor Suppressors

References & Citations

1.) Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed


2.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.

3.) Honjo, T. et al. (1992) EMBO J. 11:3887.

4.) Wurster S. et al. (2020) The Journal of Infectious Diseases 222(6):1989–994 Journal Link

Technical Protocols